Frontlight ResearchEarly access
Taking people in United StatesNo phase
Transverse Tibial Bone Transport (TTT) in the Management of Chronic Diabetic Lower Extremity Wounds
Key facts
- Who runs it
- Biodynamik, Inc
- Where
- Jacksonville, United StatesSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 15 Sept 2026
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Biodynamik XT3
- Record updated
- 14 September 2026
Who can take part
- Age
- 22 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Adults (>=22 years)
- Chronic diabetic foot ulcer wound persisting >=12 weeks and less than 104 weeks refractory to standard wound care
- Wound location within distal 1/3 tibia and below including foot
- Wound stages: WiFi >= 3
- At least one patent lower extremity tibial vessel (after revascularization if needed)
- Able to provide informed consent and comply with study procedures
Who cannot take part
- Corticosteroids >10mg prednisone equivalent daily for >2 weeks
- TNF-inhibitors or JAK inhibitors or chemotherapy-dose methotrexate
- Current participation in another investigational study (drug or device)
- Active systemic infection (positive blood cultures)
- End Stage Renal Disease requiring dialysis
- Severe hepatic impairment defined by patient on a transplant list, MELD > 20 or Child's class C
- A history of conditions that may impair wound healing in the opinion of the Investigator, for example, autoimmune disorders, renal failure patients on dialysis, or medications that impair the healing process
- Active local wound infection as defined by erythema greater than 0.5 cm from the wound margin AND at least one other localized sign of inflammation (purulent discharge, induration, localized warmth, or pain/tenderness)
- Renal function values; eGFR: <15ml/min and; Creatinine: >6mg/dL and; BUN: >50 mg/dL
- Lab values of Serum albumin less than 2.5 g/dL or hemoglobin less than 8.0 g/dL or platelet count less than 75,000/μL
- Immunocompromised (WBC <4) or undergoing active chemotherapy
- Hemoglobin A1c >10
- Severe sepsis (2 out of 4 SIRS criteria with impact on organ dysfunction)
- Subacute lower extremity wound <12 weeks with or without standard wound cares
- Internal hardware within 10cm of possible TTT placement
- Most proximal aspect of wound within 10cm of most distal pin of possible TTT placement
- Wounds less than 1 cm3 or greater than 30 cm3
- Wounds that are circumferential as defined as a wound involving 360° of the limb circumference, with complete circumferential wounds defined as 360° involvement
- Patients with osteomyelitis in the ipsilateral tibia at planned corticotomy site
- Cognitive or social limitations precluding consent or follow-up
- BMI <18.5 kg/m2
- Pregnant, lactating, or planning to become pregnant
- Life expectancy less than 12 months
Where in United States
- Mayo ClinicJacksonville, United StatesContact: Lauren EvansTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety and clinical performance of transverse tibial bone transport in patients with chronic ischemic and diabetic lower extremity ulcers. This study will assess wound healing outcomes and limb preservation in a population with limited therapeutic alternatives.
The 2 groups in the trial
- Standard of Care (control)No study treatment, for comparison
Standard Wound Care
- Standard Wound Care plus TTTTreatment being tested
Treatment: Biodynamik XT3
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- SMILE - TTT: Surgical MIcrovascularization of Lower Extremities for Diabetic Foot Ulcers - Transverse Tibial Transport Study
- Record updated
- 14 September 2026